Glenmark Pharmaceuticals Wins U.S. FDA Approval For Fluticasone Nasal Spray

Glenmark received U.S. FDA approval for generic Fluticasone Propionate Nasal Spray, therapeutically equivalent to Flonase, which had approximately $295.2 million in annual market sales through June 2026. The product will be distributed by Glenmark’s U.S. subsidiary, expanding its respiratory portfolio.